Zhu; Shuguang

Patent Applications and Registrations

Patent applications and USPTO patent grants for Zhu; Shuguang.The latest application filed is for "pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties".

Company Profile

0.8.19

Zhu; Shuguang - Shoreline WA US
Zhu; Shuguang - San Diego CA
Zhu; Shuguang - Emeryville CA
Zhu; Shuguang - Seattle WA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutically Acceptable Salts Of Quinolinone Compounds Having Improved Pharmaceutical Properties App 20140303182 - Cai; Shaopei ; et al.	2014-10-09
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-q- uinolin-2-one lactic acid salts Grant 8,614,216 - Okhamafe , et al. December 24, 2	2013-12-24
Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties App 20130338171 - Cai; Shaopei ; et al.	2013-12-19
Pharmaceutically Acceptable Salts Of Quinolinone Compounds Having Improved Pharmaceutical Properties App 20130018058 - Cai; Shaopei ; et al.	2013-01-17
Methods For Synthesizing Quinolinone Compounds App 20120277434 - Cai; Shaopei ; et al.	2012-11-01
Crystalline And Other Forms Of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-q- Uinolin-2-one Lactic Acid Salts App 20120208825 - Okhamafe; Augustus O. ; et al.	2012-08-16
Methods for synthesizing heterocyclic compounds Grant 8,222,413 - Galvin , et al. July 17, 2	2012-07-17
Crystalline And Other Forms Of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-q- Uinolin-2-one Lactic Acid Salts App 20110178097 - Okhamafe; Augustus O. ; et al.	2011-07-21
Methods For Synthesizing Heterocyclic Compounds. App 20110046376 - Galvin; Gabriel ; et al.	2011-02-24
Methods of treating cancer and related methods Grant 7,838,527 - Hannah , et al. November 23, 2	2010-11-23
Inhibition of FGFR3 and treatment of multiple myeloma Grant 7,825,132 - Cai , et al. November 2, 2	2010-11-02
Process for preparing R-gossypol L-phenylalaninol dienamine Grant 7,696,372 - Guo , et al. April 13, 2	2010-04-13
Pharmaceutically Acceptable Salts Of Quinolinone Compounds Having Improved Pharmaceutical Properties App 20090181979 - Cai; Shaopei ; et al.	2009-07-16
Process for preparing R-gossypol L-Phenylalaninol dienamine App 20090088590 - Guo; Ming ; et al.	2009-04-02
Inhibition of FGFR3 and treatment of multiple myeloma App 20050261307 - Cai, Shaopei ; et al.	2005-11-24
Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties App 20050209247 - Cai, Shaopei ; et al.	2005-09-22
Methods for synthesizing quinolinone compounds App 20050137399 - Cai, Shaopei ; et al.	2005-06-23
Methods of treating cancer and related methods App 20040220196 - Hannah, Alison ; et al.	2004-11-04
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents Grant 6,632,835 - Schmidt , et al. October 14, 2	2003-10-14
Non-steroidal estrogen receptor ligands Grant 6,599,921 - Schmidt , et al. July 29, 2	2003-07-29
Non-steroidal estrogen receptor ligands App 20020156077 - Schmidt, Jonathan Martin ; et al.	2002-10-24
1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof App 20020147187 - Schmidt, Jonathan Martin ; et al.	2002-10-10
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents App 20020115711 - Schmidt, Johnathan Martin ; et al.	2002-08-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.